Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Shield Therapeutics plc

Market Cap 68.38M 91.59M 79.02M 72.65M 128M 8.64B 130M 861M 335M 4.24B 344M 336M 14.68B P/E 2026 *
-291x
P/E 2027 * 8.67x
Enterprise Value 86.43M 116M 99.88M 91.82M 162M 10.93B 164M 1.09B 424M 5.36B 435M 425M 18.55B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.06x
Free-Float
38.23%
Yield 2026 *
-
Yield 2027 * -
1 day-15.25%
1 month-33.39%
3 months-43.38%
6 months-11.21%
Current year-45.21%
1 month 0.08
Extreme 0.08
0.09
Current year 0.08
Extreme 0.08
0.17
1 year 0.04
Extreme 0.0385
0.17
3 years 0.01
Extreme 0.0135
0.17
5 years 0.01
Extreme 0.0135
0.77
10 years 0.01
Extreme 0.0135
2.45
Manager TitleAgeSince
Chief Executive Officer 64 2024-07-23
Chief Tech/Sci/R&D Officer - 2011-12-31
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 2016-01-31
Chairman 70 2020-06-17
Director/Board Member 59 2020-06-25
Change 5-day change 1-year change 3-year change Capi.($)
-15.25%-.--% - - 91.59M
-1.20%-1.37%+17.43%-22.80% 61.85B
-2.30%-9.04%+58.88%+192.76% 55.69B
+2.78%+37.00%+37.00%+37.00% 41.88B
+1.21%+0.79%-55.33%-62.00% 36.15B
-1.87%-2.00%+54.86%-33.30% 29.33B
+0.87%+24.05%+142.44%-50.43% 24.52B
-2.53%-9.64%+42.72%+57.79% 19.78B
+1.74%+4.39%-3.12%+113.90% 16.61B
-0.59%+0.36%+56.25%+101.83% 16.2B
Average -1.76%+4.66%+39.01%+37.20% 33.56B
Weighted average by Cap. -0.40%+3.62%+35.47%+36.77%

Financials

2026 *2027 *
Net sales 55.68M 74.58M 64.34M 59.15M 105M 7.04B 106M 701M 273M 3.45B 280M 274M 11.95B 75.12M 101M 86.81M 79.81M 141M 9.5B 142M 946M 368M 4.66B 378M 370M 16.12B
Net income -74.5K -99.79K -86.09K -79.15K -140K -9.42M -141K -938K -365K -4.62M -375K -367K -15.99M 7.86M 10.53M 9.08M 8.35M 14.77M 994M 14.89M 98.97M 38.53M 488M 39.52M 38.67M 1.69B
Net Debt 18.05M 24.18M 20.86M 19.18M 33.92M 2.28B 34.2M 227M 88.48M 1.12B 90.74M 88.8M 3.87B 10.95M 14.67M 12.65M 11.63M 20.58M 1.38B 20.75M 138M 53.67M 679M 55.05M 53.87M 2.35B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0640GBP
Average target price
0.1667GBP
Spread / Average Target
+160.42%

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!